ACC’s virtual scientific session may limit impact of COVID-19 pandemic on cardiovascular research and market

Following the cancelation of the 2020 Scientific Session due to the coronavirus (COVID-19), the American College of Cardiology (ACC) has created a virtual three-day scientific session in order to minimize any impact to the advancement of cardiology research. However, this may limit the impact of the COVD-19 pandemic on cardiovascular research, says GlobalData, a leading data and analytics company.

Sheryl Tang, Principal Medical Devices Analyst at GlobalData, comments: “While the American College of Surgeons recommended minimizing, postponing, or canceling elective surgical procedures, certain cardiovascular surgical procedures and the management of cardiovascular diseases remain to be top priority. This is particularly so given the COVID-19 pandemic, as these patients are at higher risk for the novel virus. The growth of many markets across the medtech industry will experience a huge impact, however, GlobalData expects that the cardiovascular market may experience less of an impact compared to others. Prior to the COVID-19 pandemic, GlobalData estimated certain cardiology markets such as interventional cardiology and heart valve devices to grow at an average compound annual growth rate (CAGR) of 6%.”

The ACC Scientific Session will provide the latest knowledge in treatment and results from major clinical trials in all areas of cardiology, including heart failure, acute and stable ischemic heart disease, valvular heart disease, congenital heart disease and arrhythmias.

Tang concludes: “By transferring this exchange of knowledge via an online platform, support will continue to be provided to support front-line physicians providing cardiovascular care, as well as minimizing the impact to the growth of the cardiology market as a whole.”

More Media